Conclusions: Topical mupirocin appears to be a cost-effective preventive measure against gram-positive
infection in incident patients undergoing PD. The cost-effectiveness of mupirocin is affected by the level
of infection risk reduction and subject to resistance against mupirocin.
Copyright 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc.